Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. 1999

W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

DNA double-stranded breaks (dsb) activate surveillance systems that identify DNA damage and either initiate repair or signal cell death. Failure of cells to undergo appropriate death in response to DNA damage leads to misrepair, mutations, and neoplastic transformation. Pathways linking DNA dsb to reproductive or apoptotic death are virtually unknown. Here we report that metabolic incorporation of 125I-labeled 5-iodo-2'deoxyuridine, which produces DNA dsb, signaled de novo ceramide synthesis by post-translational activation of ceramide synthase (CS) and apoptosis. CS activation was obligatory, since fumonisin B1, a fungal pathogen that acts as a specific CS inhibitor, abrogated DNA damage-induced death. X-irradiation yielded similar results. Furthermore, inhibition of apoptosis using the peptide caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone did not affect CS activation, indicating this event is not a consequence of induction of apoptosis. ATM, the gene mutated in ataxia telangiectasia, is a member of the phosphatidylinositol 3-kinase family that constitutes the DNA damage surveillance/repair system. Epstein-Barr virus-immortalized B cell lines from six ataxia telangiectasia patients with different mutations exhibited radiation-induced CS activation, ceramide generation, and apoptosis, whereas three lines from normal patients failed to manifest these responses. Stable transfection of wild type ATM cDNA reversed these events, whereas antisense inactivation of ataxia telangiectasia-mutated gene product in normal B cells conferred the ataxia telangiectasia phenotype. We propose that one of the functions of ataxia telangiectasia-mutated gene product is to constrain activation of CS, thereby regulating DNA damage-induced apoptosis.

UI MeSH Term Description Entries
D007065 Idoxuridine An analog of DEOXYURIDINE that inhibits viral DNA synthesis. The drug is used as an antiviral agent. 5-Iodo-2'-deoxyuridine,IUdR,Iododeoxyuridine,5-Iododeoxyuridine,Allergan 211,Herplex Liquifilm,Idoxuridine, 123I-Labeled,Idoxuridine, 125I-Labeled,Idoxuridine, 131I-Labeled,Idoxuridine, 3H-Labeled,Idoxuridine, Radical Ion (+1),Idoxuridine, Radical Ion (1-),Kerecide,NSC-39661,Oftan-IDU,SK&F-14287,Stoxil,123I-Labeled Idoxuridine,125I-Labeled Idoxuridine,131I-Labeled Idoxuridine,3H-Labeled Idoxuridine,5 Iodo 2' deoxyuridine,5 Iododeoxyuridine,Idoxuridine, 123I Labeled,Idoxuridine, 125I Labeled,Idoxuridine, 131I Labeled,Idoxuridine, 3H Labeled,Liquifilm, Herplex,NSC 39661,NSC39661,Oftan IDU,OftanIDU
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003513 Cycloheximide Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. Actidione,Cicloheximide
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries

Related Publications

W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
July 1999, The international journal of biochemistry & cell biology,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
March 2015, The international journal of biochemistry & cell biology,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
May 2022, Molecular pharmacology,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
August 2007, Molecular cancer research : MCR,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
July 2000, Nature,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
January 2008, The international journal of biochemistry & cell biology,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
January 2010, Acta medica (Hradec Kralove),
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
February 2003, Neuroreport,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
February 2005, Cancer science,
W C Liao, and A Haimovitz-Friedman, and R S Persaud, and M McLoughlin, and D Ehleiter, and N Zhang, and M Gatei, and M Lavin, and R Kolesnick, and Z Fuks
March 2015, Molecular & cellular proteomics : MCP,
Copied contents to your clipboard!